Biogen Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BIOGEN INC, and what generic alternatives to BIOGEN INC drugs are available?
BIOGEN INC has three approved drugs.
There are seventeen US patents protecting BIOGEN INC drugs.
There are two hundred and nineteen patent family members on BIOGEN INC drugs in forty-two countries and forty-six supplementary protection certificates in thirteen countries.
Summary for Biogen Inc
| International Patents: | 219 |
| US Patents: | 17 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 3 |
| PTAB Cases with Biogen Inc as patent owner: | See PTAB cases with Biogen Inc as patent owner |
Drugs and US Patents for Biogen Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-002 | Mar 27, 2013 | AB | RX | Yes | Yes | 10,994,003 | ⤷ Sign Up | ⤷ Sign Up | |||
| Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-002 | Mar 27, 2013 | AB | RX | Yes | Yes | 10,959,972 | ⤷ Sign Up | ⤷ Sign Up | |||
| Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-001 | Mar 27, 2013 | AB | RX | Yes | No | 11,246,850 | ⤷ Sign Up | ⤷ Sign Up | |||
| Biogen Inc | ZURZUVAE | zuranolone | CAPSULE;ORAL | 217369-003 | Oct 31, 2023 | RX | Yes | Yes | 11,884,696 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-002 | Mar 27, 2013 | AB | RX | Yes | Yes | 10,391,160 | ⤷ Sign Up | ⤷ Sign Up | |||
| Biogen Inc | ZURZUVAE | zuranolone | CAPSULE;ORAL | 217369-002 | Oct 31, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Biogen Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-002 | Mar 27, 2013 | 7,320,999 | ⤷ Sign Up |
| Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-002 | Mar 27, 2013 | 8,759,393 | ⤷ Sign Up |
| Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-002 | Mar 27, 2013 | 8,524,773 | ⤷ Sign Up |
| Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-002 | Mar 27, 2013 | 7,619,001 | ⤷ Sign Up |
| Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-001 | Mar 27, 2013 | 6,509,376 | ⤷ Sign Up |
| Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-001 | Mar 27, 2013 | 8,524,773 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BIOGEN INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-releaseCapsules | 120 mg and 240 mg | ➤ Subscribe | 2017-03-27 |
International Patents for Biogen Inc Drugs
Supplementary Protection Certificates for Biogen Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2137537 | 92487 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: DIMETHYL FUMARATE. FIRST REGISTRATION: 20140203 |
| 0693475 | CR 2010 00036 | Denmark | ⤷ Sign Up | PRODUCT NAME: TAPENTADOL ((1R-2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL), HERUNDER HYDROCHLORIDET; NAT. REG. NO/DATE: 45151-45158, 45162-45169 20100830; FIRST REG. NO/DATE: EU 75043.00.00-75048.00.00, 75261.00.00-75270.00.00 20100819 |
| 2137537 | PA2014024 | Lithuania | ⤷ Sign Up | PRODUCT NAME: DIMETHYLIS FUMARAS; REGISTRATION NO/DATE: EU/1/13/837/001-002 20140130 |
| 2970101 | 8/2022 | Austria | ⤷ Sign Up | PRODUCT NAME: DIROXIMELFUMARAT; NAT. REGISTRATION NO/DATE: EU/1/21/1585 (MITTEILUNG) 20211116; FIRST REGISTRATION: LI 68066 (CH) 20210920 |
| 2653873 | 23C1003 | France | ⤷ Sign Up | PRODUCT NAME: DIMETHYL FUMARATE; REGISTRATION NO/DATE: EU/1/13/837 20140203 |
| 0605697 | SPC/GB01/008 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: 1-(((3-(2-(DIMETHYLAMINO)ETHYL)INDOL-5-YL)METHYL)SULFONYL)PYRROLIDINE GENERIC NAME ALMOTRIPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY AS ALMOTRIPTAN D,L - HYDROGEN MALATE; REGISTERED: ES 62.877 19991223; UK PL 16973/0005 20001026 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
